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OBJECTIVE—Variants in ADIPOQ have been inconsistently
associated with adiponectin levels or diabetes. Using compre-
hensive linkage disequilibrium mapping, we genotyped single
nucleotide polymorphisms (SNPs) in ADIPOQ to evaluate the
association of common variants with adiponectin levels and risk
of diabetes.
RESEARCH DESIGN AND METHODS—Participants in the
Framingham Offspring Study (n  2,543, 53% women) were
measured for glycemic phenotypes and incident diabetes over 28
years of follow-up; adiponectin levels were quantiﬁed at exam 7.
We genotyped 22 tag SNPs that captured common (minor allele
frequency 0.05) variation at r
2  0.8 across ADIPOQ plus 20 kb
5 and 10 kb 3 of the gene. We used linear mixed effects models
to test additive associations of each SNP with adiponectin levels
and glycemic phenotypes. Hazard ratios (HRs) for incident
diabetes were estimated using an adjusted Cox proportional
hazards model.
RESULTS—Two promoter SNPs in strong linkage disequilib-
rium with each other (r
2  0.80) were associated with adiponec-
tin levels (rs17300539; Pnominal [Pn]  2.6  10
8; Pempiric [Pe] 
0.0005 and rs822387; Pn  3.8  10
5; Pe  0.001). A 3-
untranslated region (3UTR) SNP (rs6773957) was associated
with adiponectin levels (Pn  4.4  10
4; Pe  0.005). A
nonsynonymous coding SNP (rs17366743, Y111H) was conﬁrmed
to be associated with diabetes incidence (HR 1.94 [95% CI
1.16–3.25] for the minor C allele; Pn  0.01) and with higher
mean fasting glucose over 28 years of follow-up (Pn  0.0004;
Pe  0.004). No other signiﬁcant associations were found with
other adiposity and metabolic phenotypes.
CONCLUSIONS—Adiponectin levels are associated with SNPs
in two different regulatory regions (5 promoter and 3UTR),
whereas diabetes incidence and time-averaged fasting glucose
are associated with a missense SNP of ADIPOQ. Diabetes 57:
3353–3359, 2008
A
diponectin is an adipokine produced by adipo-
cytes that has drawn attention over the past
few years for its potential role in diabetes
physiology (1). Adiponectin is believed to have
anti-inﬂammatory and insulin-sensitizing properties. High
levels of circulating adiponectin have been associated with
lower diabetes incidence in many prospective studies (1).
Adiponectin is encoded by the gene ADIPOQ located in
the chromosomal region 3q27. ADIPOQ spans 16 kb and
contains three exons. Previous genome-wide linkage scans
have identiﬁed 3q27 as a susceptibility locus for diabetes
(2,3). Various single nucleotide polymorphisms (SNPs) in
ADIPOQ have been reported to be associated with adi-
ponectin levels and/or diabetes but with inconsistent
results. A recent comprehensive review (4) showed that a
few ADIPOQ SNPs were associated with adiponectin
levels and insulin resistance, but none was consistently
associated with diabetes or with adiposity as measured by
BMI. As underlined by Menzaghi et al. (4), the lack of
consistent ﬁndings emphasizes the need for comprehen-
sive characterization of the genetic variation in and around
the ADIPOQ gene. They also emphasized the need to
address the issue that some ADIPOQ SNPs seem to be
associated with adiponectin levels, whereas others seem
to be associated with insulin resistance and diabetes-
related metabolic traits.
With this background in mind, we conducted a ﬁne-
mapping study of ADIPOQ, including regulatory regions
upstream and downstream of the gene. We studied partic-
ipants of the Framingham Offspring Study (FOS), a large
representative community-based sample that has been
followed prospectively for cardiovascular risk factors,
including intermediate metabolic traits and diabetes. Our
goals were to conﬁrm the associations of SNPs reported
previously, to identify SNPs that might have stronger
adiponectin or diabetes association signals than those
reported, and to seek new associations with adiponectin
levels or diabetes incidence using comprehensive charac-
terization of the gene and detailed metabolic phenotyping
From the
1General Medicine Division, Massachusetts General Hospital, Bos-
ton, Massachusetts; the
2Department of Medicine, Harvard Medical School,
Boston, Massachusetts; the
3Department of Biostatistics, Boston University
School of Public Health, Boston, Massachusetts; the
4Center for Human
Genetic Research and Diabetes Unit, Department of Medicine, Massachu-
setts General Hospital, Boston, Massachusetts; the
5Program in Medical and
Population Genetics, Broad Institute of Harvard and MIT, Cambridge,
Massachusetts; the
6Division of Endocrinology, Diabetes, and Hypertension,
Brigham and Women’s Hospital, Harvard Medical School, Boston, Massa-
chusetts; and the
7Framingham Heart Study, National Heart, Lung, and
Blood Institute, Framingham, Massachusetts.
Corresponding author: James B. Meigs, jmeigs@partners.org.
Received 23 May 2008 and accepted 22 August 2008.
Published ahead of print at http://diabetes.diabetesjournals.org on 5 Septem-
ber 2008. DOI: 10.2337/db08-0700.
J.C.F. has received consulting honoraria from Merck and from Publicis
Healthcare Communications Group, a global advertising agency engaged by
Amylin Pharmaceuticals. J.B.M. has received research grants from Glaxo-
SmithKline and has served on consultancy boards for GlaxoSmithKline,
Sanoﬁ-Aventis, Interleukin Genetics, Kalypsis, and Outcomes Sciences.
© 2008 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
ORIGINAL ARTICLE
DIABETES, VOL. 57, DECEMBER 2008 3353over a long follow-up, in a large population sample to
ensure adequate power.
RESEARCH DESIGN AND METHODS
Participants include 2,543 individuals from the FOS. This cohort, composed
almost exclusively of individuals from European descent, was commenced in
1971 and has received periodic examinations, including fasting blood tests
(5,6). This analysis includes 28 years of follow-up from exam 1 (1971–1974)
through exam 7 (1998–2002) for diabetes and cross-sectional data from exam
7. The study was approved by the institutional review board at Boston
University, and informed consent was obtained from all study participants.
Fasting total adiponectin levels were measured at exam 7, as were weight,
height, and waist circumference with the participant standing. BMI was
calculated as the weight in kilograms divided by the square of height in meters
(kg/m
2). Diabetes was deﬁned as use of diabetes therapy at any exam or
fasting plasma glucose (FPG) 7.0 mmol/l at the index exam and FPG 7.0
mmol/l on at least one prior exam. Metabolic traits included time-averaged
mean FPG over 28 years of follow-up (exams 1–7) and FPG, fasting insulin,
insulin resistance by homeostasis model assessment (7), A1C, BMI, and waist
circumference. Among diabetes-related quantitative traits that have been
collected in the FOS, we also considered in subsidiary analyses 1) at exam 5,
results of a 75-g oral glucose tolerance test (OGTT) and, derived from OGTT
results, the Gutt 0–120 min insulin sensitivity index (8); and 2) at exam 7,
visceral and subcutaneous adipose tissue volumes estimated by computerized
tomography scanning (9). FPG and insulin assays have been described (10).
Total adiponectin was measured by ELISA (R&D Systems, Minneapolis, MN).
Assay coefﬁcients of variation were 3% for glucose, 6.1% for insulin, and 5.8%
for adiponectin.
SNP selection. Using Tagger (www.broad.mit.edu/mpg/tagger), we chose tag
SNPs to cover the common variation (minor allele frequency [MAF] 0.05) in
a genomic segment spanning from 20 kb upstream to 10 kb downstream of
ADIPOQ. Arbitrary limits of the ﬂanking regions were chosen based on
current knowledge of the size of typical linkage disequilibrium regions and
distances from the gene of previously reported variants inﬂuencing gene
expression around coding sequences. Nineteen tags were initially chosen to
capture all common variants in the CEU population from Phase 2 HapMap,
accessed January 2006 (www.hapmap.org) at an r
2  0.8 using a pairwise
tagging approach. While genotyping was being completed, a new release of
HapMap became available. Reiteration of the tagging procedure with the same
settings on the newer dataset yielded a previously ungenotyped tag SNP
(rs864265), whereas rs13085499 from the original tag set was not needed to
capture all variation found in HapMap v21; the remaining tag SNPs did not
change. We included rs13085499 in our analysis for thoroughness as well as
two additional SNPs, rs2241766 (45T/G) and rs1501299 (276G/T), that had
been previously genotyped in the FOS.
Genotyping. We genotyped using iPLEX Sequenom, except rs2241766 and
rs1501299, which were genotyped by mass spectroscopy (Sequenom, San
Diego, CA). The genotyping success rate was 95% (average 98.2%), and the
consensus rate on a subset of 254 duplicate individuals was 99.4%. To
correctly estimate MAF and HWE in the SNPs, we obtained these estimates in
a maximally unrelated subset of 1,491 individuals selected by choosing one
person per pedigree. All of the SNPs were in HWE (P  0.01 for all but
rs182052, whose HWE P value was 0.0002).
Statistical analysis. Quantitative traits were regressed against covariates to
produce Studentized residuals that were used as the dependent variable in the
subsequent genetic models. To examine the strength of the SNP associations
accounting for overall adiposity, we used two covariate adjustment schemes:
sex, age (per year), and age
2 and sex, age, age
2, and BMI (per kg/m
2) adjusted.
The association between each trait residual and each SNP was assessed using
a linear mixed effects (LME) model implemented in SOLAR (11) to account for
within-family correlations. Each SNP was included in a model as a ﬁxed effect
with additive coding. Subsidiary analyses were performed with recessive and
dominant models with the main traits of interest (adiponectin levels, mean
glucose, and diabetes survival). The models included random effects to
account for the covariance between family members; the covariance structure
was determined by the degree of relatedness between each relative pair.
To assess SNP associations with the diabetes phenotype, we used Cox
proportional hazards survival analysis with diabetes as the outcome and the
survival time as the age at the exam at which diabetes was ﬁrst determined.
The survival time of individuals without diabetes was the age at their last
exam. The model was implemented with the survival package in R (12), with
the same adjustments as in the LME models, with covariates taken at the ﬁrst
exam. Trait correlation among siblings was modeled with a frailty term in the
survival model (13). We provide power calculation for diabetes incidence in
supplementary Table 9, available in an online appendix at http://dx.doi.org/
10.2337/db08-0700. We conducted subsidiary analysis using incidence of
hyperglycemia (deﬁned as fasting blood glucose 100 mg/dl on two exams
during follow-up).
Statistical signiﬁcance was determined using an empirical P value obtained
by a simulation strategy, which generated a null distribution of minimum P
values. We simulated a trait for our sample using SIMQTL in SOLAR (11). The
heritability of the trait was 35%, although similar null distributions were
obtained for heritabilities of 15 and 50%. The simulated trait was analyzed in
the same manner as the trait residuals, using LME models implemented in
SOLAR, and the minimum P value observed over all of the SNPs was recorded.
Ten thousand traits were generated to create an empirical distribution of
minimum P values. This strategy provides correction for correlation among
the SNPs but does not correct for the multiple traits being tested. We report
both nominal (Pn) and empiric (Pe) P values.
Multiple SNP models. To assess whether association signals were due to
linkage disequilibrium among the SNPs or were independent, we sequentially
added SNPs to LME models. If the signals were independent, we expected that
they would each remain signiﬁcant in these models. Alternatively, if any
became nonsigniﬁcant, we would conclude that the positive associations were
due to the tag SNP remaining signiﬁcant in the multi-SNP model.
BMI stratiﬁcation and interaction models. As exploratory analyses, we
assessed the effects of BMI on the associations between all SNPs and the main
traits of interest (adiponectin levels, mean glucose over follow-up, and
diabetes incidence) by testing the associations stratiﬁed by obesity status
(nonobese, i.e., BMI 30 kg/m
2, and obese, i.e., BMI 30 kg/m
2). We also
tested the presence of interactions between BMI and each SNP for the same
traits.
RESULTS
The clinical characteristics of study participants are pre-
sented in Table 1. Mean adiponectin levels were 7.4  4.5
	g/ml for men and 12.4  6.4 	g/ml for women. Charac-
teristics at exam 5, including the OGTT results, are pre-
sented in supplementary Table 1, and exam 7 adiposity
measures by computed tomography are in supplementary
Table 2, both of which are available in the online appendix.
Details of the genotyped SNPs are presented in Table 2.
The tag SNPs captured 100% of SNPs passing quality
control with an r
2 0.80 and an MAF 0.05. The details of
all SNPs captured by our tagging approach are available in
supplementary Table 3 in the online appendix. The SNPs
span 45,832 bp, with an average inter-SNP distance of
1,706 bp. A nonsynonymous coding SNP located in exon 3
(rs17366743 [Y111H]) had an MAF of 0.036 in the FOS but
TABLE 1
Characteristics at entry and at exam 7 of 2,543 FOS participants
genotyped for ADIPOQ variants
n Mean  SD
Total individuals genotyped (n) 2,543
Unrelated (n) 1,448
Pedigrees (n) 282
Sibpairs (n) 994
Avuncular pairs (n)6 6
Cousins (n) 653
Sex (% women) 2,543 53
Age at entry (exam 1) (years) 2,543 34.6  9.8
BMI at entry (exam 1) (kg/m
2) 2543 24.9  4.3
Cases of diabetes over 28 years (n) 244
Mean glucose from exams 1–7 (mg/dl) 2,543 99.3  16.9
Exam 7
BMI (kg/m²) 2,405 28.2  5.4
Waist circumference (inches) 2,388 39.3  5.6
Fasting glucose (mg/dl) 2,371 104.3  26.6
Fasting insulin (	U/ml) 2,292 14.8  8.7
HOMA-IR 2,292 4.0  3.2
A1C (%) 2,189 5.7  1.0
Plasma adiponectin (	g/ml) 2,018 10.0  6.1
HOMA-IR, homeostasis model insulin resistance calculated by 
fast-
ing glucose  fasting insulin/22.5.
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sample. Allele frequencies were otherwise similar to Hap-
Map frequencies.
Supplementary Fig. 1, available in the online appendix,
illustrates the linkage disequilibrium map of the 35 SNPs.
As previously reported, ADIPOQ is composed of two
regions of high linkage disequilibrium, one covering the
5-promoter region, and the second including intron 2,
exon 3, and the 3-untranslated region (3UTR), separated
by a segment of high recombination rate.
Adiponectin levels were available in 2,018 genotyped
participants. Figure 1 illustrates the association of SNPs
with adiponectin levels and the strength of their associa-
tion (expressed as log P) adjusted for sex, age, and age
2
or for sex, age, age
2, and BMI. The minor A allele (MAF 
0.10) at SNP rs17300539 (11391G/A), located in the
promoter region, showed the strongest association with
higher adiponectin levels under an additive model
(Pn  2.6  10
8; Pe  0.0005). Also in the 5–linkage
disequilibrium region, the minor C allele at rs822387
(MAF  0.10) was strongly associated with higher adi-
ponectin levels (Pn  3.8  10
5; Pe  0.001) and was in
strong linkage disequilibrium (r
2  0.794 in unrelated
members of the FOS) with rs17300539.
In the 3UTR, the minor A allele at rs6773957 (MAF 
0.41) showed the strongest association with higher adi-
ponectin levels (Pn  4.4  10
4; Pe  0.005). Located
further downstream in the 3 region, rs6444175 showed a
nominal trend of association with adiponectin levels that
did not remain signiﬁcant after multiple testing correction
(Pn  0.017; Pe  0.2); however, further adjustment for
BMI seemed to strengthen the association (Pn  0.003;
Pe  0.04). Also, in the second linkage disequilibrium
region, rs1501299 (276G/T; located in intron 2) showed a
nominal association with adiponectin levels once adjusted
for BMI (Pn  0.007), but the empiric P value was not
signiﬁcant (Pe  0.10). The two latter SNPs (rs6444175 and
rs1501299) are in strong linkage disequilibrium with each
other (r
2  0.92) and in moderate linkage disequilibrium
with rs6773957 (r
2  0.5). A few other SNPs had nominal
associations with adiponectin levels; all of the details for
each SNP association with adiponectin levels (without and
with adjustment for BMI) are shown in Table 3.
Diabetes incidence was associated with only one SNP,
rs17366743 (Y111H), which is a nonsynonymous SNP
FIG. 1. Negative log base 10 of the P value for genetic associations for
adiponectin levels under the additive model (left y-axis), graphed
versus SNPs in the ADIPOQ region arranged by chromosomal position
(x-axis). The continuous line marked by the right y-axis indicates the
recombination rate. The ADIPOQ gene is shown by the horizontal
arrow at the bottom of the plot. , Traits adjusted for sex and age; ,
additional adjustment for BMI.
TABLE 2
Characteristics of 22 SNPs genotyped in and around ADIPOQ in 2,543 men and women in the FOS
SNP
Previous name in
the literature
Location on
chromosome
3 (NCBI 35) Relation to gene Call rate
HWE
P value
Major
allele
Minor
allele MAF
rs10937273 188032397 5 of promoter 0.951 0.013 G A 0.43
rs864265 188036994 5 of promoter 0.967 0.071 G T 0.14
rs822387 188038739 5 of promoter 0.995 0.816 T C 0.10
rs16861194 11426A/G 188042127 Promoter 0.991 0.290 A G 0.07
rs17300539 11391G/A 188042162 Promoter 0.984 0.816 G A 0.10
rs266729 11377C/G 188042176 Promoter 0.980 0.055 C G 0.27
rs182052 188043484 Intron 1 0.993 0.0002 G A 0.33
rs822391 188046505 Intron 1 0.963 0.686 T C 0.19
rs822396 188049579 Intron 1 0.995 0.784 A G 0.19
rs12495941 188050882 Intron 1 0.951 0.781 G T 0.35
rs7649121 188051487 Intron 1 0.994 0.893 A T 0.19
rs17366568 188053155 Intron 1 0.977 1.000 G A 0.11
rs2241766 45T/G 188053594 Exon 2 coding synonymous 0.748 0.182 T G 0.15
rs1501299 276G/T 188053825 Intron 2 0.727 0.623 G T 0.26
rs3821799 188054188 Intron 2 0.994 0.802 C T 0.46
rs3774262 188054516 Intron 2 0.994 0.597 G A 0.14
rs17366743 Y111H 188054791 Exon 3 coding nonsynonymous 0.996 1.000 T C 0.04
rs6773957 188056407 3UTR 0.988 0.796 G A 0.41
rs6444175 188062446 3 of 3UTR 0.982 0.459 G A 0.27
rs13085499 188063542 3 of 3UTR 0.982 0.933 A G 0.47
rs7628649 188068083 3 of 3UTR 0.990 0.113 C T 0.14
rs17373414 188068229 3 of 3UTR 0.979 0.186 C T 0.13
Call rate, success rate of genotyping each SNP in the FOS sample; HWE P value, Hardy-Weinberg equilibrium test P values, with signiﬁcance
set at 0.0001. MAF, MAF in the FOS, calculated from a subsample of 1,491 unrelated participants.
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DIABETES, VOL. 57, DECEMBER 2008 3355coding for a Y3H change at codon 111 in exon 3 of
ADIPOQ. In age-sex adjusted analysis, those carrying the
minor C allele (MAF  0.036) were associated with a
hazard ratio (HR) of 1.94 for incident diabetes (95% CI
1.16–3.25; Pn  0.01). rs17366743 also was associated with
28-year time-averaged mean FPG (Pn  0.0004; Pe 
0.004); consistent with our diabetes survival analysis, the
minor C allele was associated with higher glucose levels.
We had limited power to see smaller effects (HR 1.1–1.4)
on diabetes incidence, even with higher MAF (supplemen-
tary Table 9). Figure 2 summarizes the associations of
SNPs in ADIPOQ with diabetes incidence and mean FPG.
A few SNPs also showed trends of associations with other
glycemic quantitative traits, but none remained statisti-
cally signiﬁcant after empiric correction (supplementary
Tables 4 and 5, available in the online appendix). Subsid-
iary analysis did not show any SNP to be signiﬁcantly
associated with incidence of hyperglycemia (affecting
52.7% of the FOS) (supplementary Table 10, available in
the online appendix).
Concerning adiposity, we did not ﬁnd an association
between any SNPs in ADIPOQ and adiposity measure-
ments, including BMI, waist circumference, or visceral and
subcutaneous adipose tissue volumes (supplementary Ta-
bles 4–6). In the obesity-stratiﬁed analyses, our main
ﬁndings seemed to have a similar effect on adiponectin
levels in both nonobese and obese strata; whereas two
SNPs (rs17366568 and rs864265) appeared to have a
stronger effect in the obese population. There was no
signiﬁcant interaction between any of the SNPs and BMI
on diabetes incidence. All of the details for each SNP
association with adiponectin levels, mean glucose, and
diabetes incidence stratiﬁed by obesity status and tested
for interaction with BMI are presented in supplementary
Table 8, available in the online appendix.
In the 5–linkage disequilibrium region–multiple SNPs
model, both rs17300539 and rs822387 remained signiﬁ-
cantly associated with adiponectin levels, indicating
that despite their strong linkage disequilibrium, they
may represent independent signals. In the 3–linkage
disequilibrium region, including rs6773957, rs6444175,
TABLE 3
Adiponectin levels for each SNP in and around ADIPOQ in the FOS
SNP
Position on
chromosome
3 (NCBI 35) n
Alleles
M/m M/M M/m m/m
P value
(adjusted
for sex,
age, and
age
2)
Empiric
P value*
P value
(adjusted
for sex,
age, age
2,
and BMI)
Empiric
P value†
rs10937273 188032397 1,870 G/A 10.07  6.39 10.11  6.1 9.53  5.53 0.91 1.0 0.79 1.0
rs864265 188036994 1,885 G/T 10.14  6.17 9.74  6.03 9.05  4.83 0.09 0.71 0.03 0.38
rs822387 188038739 1,949 T/C 9.81  6.09 10.9  6.1 11.52  4.97 3.77  10
5 0.001 1.96  10
5 0.001
rs16861194 188042127 1,942 A/G 10.02  5.98 9.8  6.76 7.7  5.08 0.06 0.57 0.05 0.53
rs17300539 188042162 1,929 G/A 9.71  6.06 11.5  6.21 11.56  5.25 2.64  10
8 0.0005 1.46  10
8 0.0005
rs266729 188042176 1,921 C/G 9.96  5.9 9.96  6.28 10.43  6.58 0.46 1.0 0.25 0.98
rs182052 188043484 1,949 G/A 10.01  5.69 9.95  6.38 10.2  6.64 0.12 0.83 0.04 0.47
rs822391 188046505 1,898 T/C 9.98  6.09 9.99  6.14 9.24  5.84 0.62 1.0 0.49 1.0
rs822396 188049579 1,947 A/G 10  6.08 10.07  6.11 9.17  6.1 1.0 1.0 0.92 1.0
rs12495941 188050882 1,876 G/T 10.09  6.28 10.1  6.16 9.35  5.51 0.40 1.0 0.53 1.0
rs7649121 188051487 1,947 A/T 9.9  5.94 10.16  6.24 9.99  6.89 0.99 1.0 0.83 1.0
rs17366568 188053155 1,917 G/A 10.07  6.02 9.61  6.41 10.6  5.8 0.03 0.38 0.01 0.15
rs2241766 188053594 1,499 T/G 9.9  6.07 10.4  6.45 9.88  4.66 0.13 0.85 0.14 0.88
rs1501299 188053825 1,459 G/T 9.93  6.42 10.01  5.69 10.39  5.49 0.05 0.50 0.007 0.10
rs3821799 188054188 1,947 C/T 9.79  6.29 10.11  6.15 10.05  5.55 0.10 0.75 0.07 0.66
rs3774262 188054516 1,947 G/A 9.86  6.03 10.49  6.29 10.35  6.14 0.11 0.81 0.15 0.88
rs17366743 188054791 1,952 T/C 9.99  6.07 10.23  6.32 NA  NA 0.54 1.0 0.42 1.0
rs6773957 188056407 1,933 G/A 9.58  6.23 10.24  6.16 10.21  5.35 0.0004 0.005 0.0001 0.002
rs6444175 188062446 1,926 G/A 9.84  6.34 10.19  5.88 10.12  5.7 0.03 0.21 0.003 0.04
rs13085499 188063542 1,928 A/G 9.91  6.33 10.08  6.12 9.93  5.75 0.32 0.99 0.24 0.98
rs7628649 188068083 1,938 C/T 9.94  6.09 10.2  6.03 10.4  6.26 0.65 1.0 0.66 1.0
rs17373414 188068229 1,924 C/T 9.84  6.01 10.64  6.51 8.99  5.25 0.03 0.32 0.01 0.16
Data are means  SD. M, Major allele; m, minor allele. *Empiric P value calculated by simulation strategy form the P values adjusted for sex,
age, and age
2. †Empiric P value calculated by simulation strategy form the P values adjusted for sex, age, age
2, and BMI.
FIG. 2. Negative log base 10 of the P value for genetic associations with
diabetes survival (circles) and mean glucose over 29 years of follow-up
(diamonds) under the additive model (left y-axis), graphed versus
SNPs in the ADIPOQ region arranged by chromosomal position (x-
axis). The continuous line marked by the right y-axis indicates the
recombination rate. The ADIPOQ gene is shown by the horizontal
arrow at the bottom of the plot. Open symbols indicate traits adjusted
for sex and age; closed symbols indicate additional adjustment for BMI.
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signiﬁcance for all three SNPs, indicating that they prob-
ably represent the same signal, with rs6773957 having the
strongest individual effect. Finally, we examined a model
with all SNPs associated with adiponectin levels. Only the
two SNPs in the promoter region (rs17300539 and
rs822387) remained signiﬁcant in the model.
We performed subsidiary analyses using recessive and
dominant genetic models for the main traits of interest.
The results are presented in supplementary Table 7, avail-
able in the online appendix. In brief, dominant model
results were very similar to the additive model, whereas
recessive models showed similar direction of effect but no
signiﬁcant association. Some trends for SNPs other than
the ones observed in the additive models were seen, but
we consider those ﬁndings exploratory.
DISCUSSION
In the community-based FOS, we found that adiponectin
levels were associated with SNPs located in two distinct
regulatory regions around the ADIPOQ gene. SNPs in the
promoter region associated with adiponectin levels con-
ﬁrm previous reports (rs822387 and rs17300539) (4,14).
Our detailed mapping allowed us to detect that adiponec-
tin levels were also associated with previously unreported
SNPs in or near the 3UTR (rs6773957 and rs6444175).
Given their linkage disequilibrium pattern, one of these
novel SNPs might account for the previously reported
association between rs1501299 (276G/T) and adiponec-
tin levels (4). Diabetes incidence and time-averaged mean
glucose were associated with rs17366743, a nonsynony-
mous coding SNP, conﬁrming previous reports (15–17).
Adiponectin levels and SNPs in the 5-promoter
region. We found that the minor C allele rs822387 was
associated with higher adiponectin levels, conﬁrming the
report of Heid et al. (14). As reported in both studies,
rs822387 is in strong linkage disequilibrium with the
promoter SNP rs17300539, but both SNPs remained statis-
tically signiﬁcant when considered jointly in the LME
model. This suggests that they may both have an indepen-
dent effect on adiponectin levels, but it would be difﬁcult
to afﬁrm this with certitude because of their very strong
mutual linkage disequilibrium.
Two SNPs in the promoter region have been frequently
genotyped in ADIPOQ association studies: rs17300539
(11391G/A) and rs266729 (11377C/G). Our ﬁndings are
consistent with Menzaghi et al. (4), by whom the minor A
allele at rs17300539 was reported to be associated with
higher adiponectin levels in a meta-analysis of 2,000
individuals. Furthermore, rs17300539 was shown to have a
functional role in in vitro data: The A allele seemed to
enhance the ADIPOQ promoter activity and increased
transcriptional activity (18). rs266729 did not meet the
inclusion criteria for the meta-analysis of Menzaghi et al.
(4). Some studies have reported that rs266729 was associ-
ated with adiponectin levels (16), whereas others did not
(19); it seemed that the level of obesity of the population
studied might have played a role in revealing the associa-
tion (17,19). Cauchi et al. (20) also suggest that obesity
status contributes to the association between rs266729
and diabetes. We did not ﬁnd a BMI  genotype interac-
tion in the association between rs266729 and adiponectin
levels or diabetes incidence. Our negative results are
consistent with either false-positive ﬁndings in the initial
reports or lack of power in the current study.
Adiponectin levels and SNPs in the 3UTR region.
Another SNP often genotyped in ADIPOQ studies was
rs1501299 (276G/T). In our analysis, the minor T allele
was nominally associated with higher adiponectin levels,
consistent with Menzaghi et al. (4). However, in vitro data
has not supported a functional role for rs1501299 in
adiponectin expression (18). It has been proposed that
rs1501299 might be a marker, through linkage disequilib-
rium, of a functional variant in the 3UTR region (4). A
novel 3UTR SNP, rs6773957, showed the strongest signal
in this region of ADIPOQ. Others have reported other
SNPs in the 3UTR nominally associated with adiponectin
levels (14,19). At this time, we could not ﬁnd any published
functional data directly addressing SNPs in the 3UTR to
conﬁrm that any of these SNPs might be the cause of
change in adiponectin levels. More in vitro studies are
needed to discover the functional role of one or many of
the variants in the 3UTR.
By extending our mapping up to 10 kb downstream to
the ADIPOQ in the 3 region, we found that minor A allele
at rs6444175 was associated with higher adiponectin lev-
els. This newly reported SNP is in moderate linkage
disequilibrium with rs6773957 (r
2  0.51 in the FOS) and
in strong linkage disequilibrium with rs1501299 (r
2 
0.92). Using genetic association alone, we cannot distin-
guish which of the three SNPs (rs6773957, rs1501299 or
rs6444175) is driving the association signal; the results of
multiple regression analysis indicate that the effect of
these three SNPs were not independent. Also, the multiple
SNPs analysis including all SNPs associated with adi-
ponectin levels in our data showed that only the promoter
SNPs remained signiﬁcantly associated in the model. This
might be because the association signal in the 3 region
may be driven by the association stemming from the
promoter SNPs, despite the high recombination rate and
the low linkage disequilibrium between the two regions
(r
2  0.12 for rs17300539 with rs6773957).
Diabetes and glycemic traits. Diabetes incidence over
28 years was nominally associated with rs17366743
(Y111H). This amino acid change from a Tyr (T allele) into
a His (C allele) in position 111 of the adiponectin protein
is located at the hinge between the collagen and the
globular domains of adiponectin. It has been hypothesized
that such a change might alter the spatial organization and
the function of the protein by hindering the complexation
of collageneous homotrimers in bundles (16). Directed
functional changes in coding sequence have not shown
that Y111H alters the high molecular weight formation of
adiponectin, in contrast to other coding mutants (21);
rather, Y111H is believed to disrupt the exonic splicing
enhancer, which could inﬂuence alternative splicing of the
message (http://fastsnp.ibms.sinica.edu.tw). Mutations in
the exonic splicing enhancer have been shown in other
examples of increased genetic risk for diseases, including
the BRCA1 gene in breast cancer (22). Therefore, even if
rs17366743 does not inﬂuence the level of the circulating
adiponectin, it could inﬂuence the functionality of the
protein and so decrease the insulin-sensitizing role of
adiponectin, putting carrier individuals at higher risk of
diabetes. The minor C allele of rs17366743 is relatively rare
in Framingham (3.6%) but somewhat more frequent in
HapMap CEU subjects (7.5%). Our ﬁndings are consistent
with the report by Vasseur et al. (16) and Ukkola et al. (15)
but in contrast to the ﬁndings of Gu et al. (23). We
accessed the DIAGRAM dataset (http://www.well.ox.
ac.uk/DIAGRAM/) to look for other replications. Unfortu-
M.-F. HIVERT AND ASSOCIATES
DIABETES, VOL. 57, DECEMBER 2008 3357nately, because rs17366743 is a rare SNP, it was not
genotyped directly, and its best proxy in HapMap Euro-
pean descent (rs7649121) offered low linkage disequilib-
rium (r
2  0.17), but the effect was in the same direction
(P  0.009).
The association of rs17366743 with time-averaged FPG
in our data increases our conﬁdence that this is a true
ﬁnding and not a result of type 1 error. In the HERITAGE
Family Study, the minor C allele was associated with a
lower sensitivity index and a higher acute insulin response
to glucose during an intravenous glucose tolerance test
but not with the disposition index, suggesting higher
insulin resistance and a compensatory response in individ-
uals carrying the risk allele (15). In contrast, Heid et al.
(14) did not ﬁnd an association between Y111H and any of
the parameters of the metabolic syndrome. In fact, despite
extensive mapping and detailed phenotyping in their large
sample, none of the SNPs genotyped by Heid et al. (14)
was reported to be signiﬁcantly associated with parame-
ters of the metabolic syndrome. Similarly, very few SNPs
other than rs17366743 were nominally associated with
metabolic traits in our dataset. The reasons for such
sparse ﬁndings might be related to the fact that glycemic
and metabolic traits are inﬂuenced by so many genetic and
environmental factors that the contribution of ADIPOQ
variants is difﬁcult to capture.
Strengths and limitations. Strengths of our study in-
clude high-quality genotyping, comprehensive coverage of
ADIPOQ and its ﬂanking regions, the statistical power
afforded by a large number of participants in a general
community sample including a family-based component,
and standardized phenotyping over 28 years of follow-up.
Nevertheless, this study has a few limitations. We mea-
sured total adiponectin and not the high molecular weight
fraction, which has been proposed to have a stronger
correlation with insulin resistance compared with total
adiponectin (24). Also, adiponectin levels were measured
at exam 7 (the last follow-up examination); results might
have been different if adiponectin was measured earlier
during the follow-up. If adiponectin truly lies on the causal
pathway of diabetes development, measurements of adi-
ponectin levels at the beginning of follow-up might have
revealed associations between the relevant SNPs and both
protein levels and diabetes incidence, in line with the
concept of Mendelian randomization. We had limited
power to test this concept: for example, for promoter SNP
rs17300539 (our strongest signal associated with adiponec-
tin levels), according to an additive model, each minor
allele (MAF  0.10) increases adiponectin levels by 1.63
	g/ml, and assuming that each 1 	g/ml increase in
adiponectin levels decreases diabetes risk incidence by
8.1% (24), we had 10% power to detect the effect of
rs17300539 on diabetes incidence. Some previous asso-
ciations could not be replicated; whether this is due to
a false-positive original result or insufﬁcient power to
detect it in our samples is not clear. Also, novel associa-
tions need independent replication before we can conﬁ-
dently claim they represent true ﬁndings. Our sample is of
European origin, and our ﬁndings may not be generaliz-
able to populations with different linkage disequilibrium
patterns. Finally, genetic associations do not prove that
the SNP is the direct cause of the defect; ﬁne-mapping and
functional studies are needed to identify the true causal
variants.
Conclusions. We conﬁrmed signiﬁcant associations be-
tween adiponectin levels and ADIPOQ SNPs in the 5-
promoter region (rs17300539 and rs822387) while
unmasking a new association in the downstream 3UTR
region (rs6773957 and rs6444175). On the basis of linkage
disequilibrium measures, we believe those two regions
represent distinct association signals, and thus, adiponec-
tin levels seem to be inﬂuenced by both regulatory seg-
ments. In addition, diabetes survival and mean glucose
were associated with the nonsynonymous SNP rs17366743
(Y111H), which might inﬂuence alternative splicing. Ac-
cording to the hypothesis of Mendelian randomization, a
causal variation in the genome should inﬂuence both the
levels of a biomarker and the risk of disease. Our ﬁndings
do not preclude the existence of the concept of Mendelian
randomization but underline that it might not be always
straightforward to demonstrate it, particularly when both
effect sizes (that of genotype on the intermediate pheno-
type and that of the intermediate phenotype on the clinical
endpoint) are modest. Our results suggest that the alter-
ation in adiponectin function induced by SNP rs17366743
(Y111H) may have stronger effects than the change in
levels induced by SNPs in the regulatory regions; thus,
different variants in the same gene might be related to
biomarker levels but not sufﬁciently to bring about asso-
ciated disease states, and vice versa.
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